OPORF News and Press, Open Orphan plc From 06/28/23

(NewsDirect) hVIVO PLC (AIM:HVO) chief executive Mo Khan speaks to Thomas Warner from Proactive after announcing that the specialist contract research organisation has partnered with a North American biopharmaceutical company to create the industry's first commercial hMPV human challenge ...

(NewsDirect) hVIVO PLC (AIM:HVO) chief executive Mo Khan speaks to Thomas Warner from Proactive after releasing audited results for 2022 - a year that he describes as "transformational" for the specialist contract research organisation. Khan gives his highlights from the results befor...

(NewsDirect) hVIVO PLC (AIM:HVO) Director of Business Development for Europe and Asia Egle Pavyde speaks to Proactive's Thomas Warner after announcing the company's second contract win of the year in the Asia-Pacific region. Pavide reveals more details about the contract and says she is delig...

(NewsDirect) hVIVO PLC (AIM:HVO) chief executive Mo Khan speaks to Proactive's Thomas Warner after releasing a trading update for 2022 that shows the specialist contract research organisation achieved "record results" in 2022. Khan reveals the reasons for the improvement in the performance of...

(NewsDirect) Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com Copyright (c) 2023 TheNewswire - All rights reserved.

The world's first "human challenge" study in volunteers who were exposed to the novel coronavirus suggested that having symptoms did not have an effect on how likely an infected person may communicate the disease on to other people. The study was conducted by Open Orphan's (OTCPK:OPORF) ...

AIM ImmunoTech (NYSE:AIM) and hVIVO, a subsidiary of Open Orphan (OTCPK:OPORF) have a signed Clinical Trial Agreement for a Phase 2a Human Challenge Trial (HCT) to test AIM's drug Ampligen as a potential intranasal prophylactic using a human rhinovirus (HRV-16, a common cold virus) and i...